ALEXANDRIA, Va., March 3 -- United States Patent no. 12,564,608, issued on March 3, was assigned to Exocure Sweden AB (Goeteborg, Sweden).
"Use of ghost nanovesicles as therapeutics" was invented by Jan Lotvall (Lysekil, Sweden) and Kyong-su Park (Gothenburg, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides ghost nanovesicles (gNVs) that are deficient in cytosolic components. Methods of making such vesicles and therapeutic uses of such vesicles are also provided. The gNVs may be used in preventing or treating conditions that may benefit from administration of the gNVs. Such conditions include conditions that involve inflammation."
The patent was filed on Sept. 11, 2020, ...